Grupo de Investigación en Cáncer de Mama
NEONCOBREAST
University of Cambridge
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de University of Cambridge (3)
2020
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210